Labcorp to Expand Clinical Trial Operations in Brazil with Dedicated Kit Assembly and Future Laboratory Operations through Collaboration with Grupo Fleury
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Labcorp (NYSE: LH) announced a collaboration with Grupo Fleury to expand clinical trial operations in Brazil through local services. Labcorp plans to introduce clinical trial kit assembly in early 2027, followed by laboratory operations expected to launch by the end of 2027. The laboratory operations remain in development.
Grupo Fleury will support the new operations, which will use Labcorp's global systems, processes and quality standards for multinational clinical trials. The collaboration extends Labcorp's clinical trial support capabilities across five continents, alongside its wholly owned central laboratory network in North America, Europe, Asia and Africa. Labcorp expects the Brazil operations to shorten kit delivery times, reduce reliance on international shipping and improve operational efficiency for trial sponsors.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.Brazil kit assembly operations are expected to begin in early 2027 through the Grupo Fleury collaboration.
- Minor point. Forward-looking: it has not happened yet and may not happen.Brazil laboratory operations are expected to launch by the end of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Brazil expansion is expected to shorten kit delivery times and reduce reliance on international shipping.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expansion will bring clinical trial services closer to research sites and patients while supporting global studies
Labcorp's wholly owned central laboratory network spans
"Clinical trials today often span multiple countries, and sponsors need partners that can combine global expertise with local insight," said Brian Caveney, M.D., president, biopharma laboratory services and chief medical and scientific officer, Labcorp. "Our expansion in
"
Local kit assembly is expected to begin in early 2027, while laboratory operations remain in development and are expected to launch by the end of 2027. Both operations will use Labcorp's global systems, processes and quality standards to support multinational clinical trials.
By establishing operations in
To learn more, visit: https://www.labcorp.com/biopharma/central-labs/locations.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements about the planned expansion of clinical trial operations into Brazil, with local kit assembly anticipated to be established in early 2027 and laboratory operations to follow by the end of 2027, and the expected benefits to clinical trial sponsors from Labcorp's expanded global footprint.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond Labcorp's control. These factors, in some cases, have affected and in the future (together with other factors) could affect Labcorp's ability to implement its business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in Labcorp's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in subsequent quarterly reports on Form 10-Q and its other filings with the SEC. The information in this press release should be read in conjunction with a review of Labcorp's filings with the SEC including the information in its most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-to-expand-clinical-trial-operations-in-brazil-with-dedicated-kit-assembly-and-future-laboratory-operations-through-collaboration-with-grupo-fleury-302942468.html
SOURCE Labcorp
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Labcorp launch its clinical trial operations in Brazil?
Local clinical trial kit assembly is expected to begin in early 2027, while laboratory operations are expected to launch by the end of 2027. The laboratory operations remain in development, and both operations will use Labcorp's global systems, processes and quality standards.